RenBio
Business Services · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
430 E 29th St Ste 600, New York City, Ne...Phone Number
(646) 440-9410Website
www.renbio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
2
1
1
About RenBio
RenBio is a privately-held, preclinical biotechnology company developing novel, best-in-class antiviral antibody therapeutics and a next-generation antibody delivery platform. The company was established in 2016 and is headquartered out of New York City, NY.Explore more
RenBio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is RenBio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at RenBio
Check out if RenBio is spiking on competitors!
Product Launch: Get notified when RenBio launches new products
Website visits: Recent activity has been detected on your website
RenBio, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if RenBio had a recent Job posting/layoffs
Earning: See what the market has to say on RenBio recently announced quarterly report
Funding: Get notified immidiatlly once RenBio has new funding data
Check if RenBio has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined RenBio as Masked Content
Find 3 more new buyers
Compare Similar Companies to RenBio
Compare insights from companies similar to RenBio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
RenBio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
RenBio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about RenBio.
RenBio financials insights
Gather financial insights about RenBio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$150K
2021
Debt
$264K
Series A
$24M
RenBio Tech Stack
A closer look at the technologies used by RenBio
Most Recent Scoops
Funding
Funding
RenBio has received an SBA PPP loan in the amount of $264,760 from JPMorgan Chase resulting in the retention of 11 jobs.
Funding
RenBio has received an SBA PPP loan for $150,000-350,000 from JPMorgan Chase Bank.
Funding
RenBio News & Media
RenBio Announces the Award of Two Grants to Support Continued Development of Its Novel DNA Therapeutics MYO Technology™ Platform for Infectious Disease Applications
$2.0 Million Grant from the New York State Biodefense Commercialization Fund Approximately $1.0 Million Received as Sub-Awardee of Vanderbilt University Under DARPA's Pandemic Prevention Platform (P3) Program NEW YORK, Oct. 12, 2022 /PRNewswire/ -- RenBio, a privately-held, preclinical...RenBio Completes $24 Million Series A Financing and Licenses Novel SARS-CoV-2 Bispecific Antibody from Columbia University
NEW YORK, May 20, 2021 /PRNewswire/ -- RenBio, a privately-held, preclinical biotechnology company developing novel, best-in-class antiviral antibody therapeutics and a next-generation antibody delivery platform, today announced that it has completed a $24 million Series A financing, led...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding RenBio
Sign Up For FreeTo access detailed company insights
RenBio is a privately-held, preclinical biotechnology company developing novel, best-in-class antiviral antibody therapeutics and a next-generation antibody delivery platform. The company was established in 2016 and is headquartered out of New York City, NY.... Read More
